2026 Exam All Answers and
Illustrations Given
Which division has primary jurisdiction over a vascular graft with an
antibiotic based on primary mode of action?
A. CDER
B. CBER
C. CDRH
D. OCP - ANSWER ✔✔C. CDRH
,In this combination of a device and a drug, the primary mode of action is
that of the vascular graft (device). The antibiotic is supportive in this
case.
A company wants to modify its legally marketed device such that the
modification does not affect the intended use or alter the fundamental
scientific technology of the device. If the design outputs of the modified
device meet the design input requirements, this change would be best
filed as a(n):
A. Special 510(k)
B. Abbreviated 510(k)
C. Traditional 510(k)
D. De novo 510(k) - ANSWER ✔✔A. Special 510(k)
A Special 510(k) is allowed if a modification to the legally marketed
device is being made that relies on compliance with design controls,
including design validation. The incentive provided for manufacturers to
choose this option is that ODE intends to process special 510(k)s within
,30 days of receipt. See the CDRH guidance published in 1998 entitled
The New 510(k) Paradigm - Alternate Approaches to Demonstrating
Substantial Equivalence in Premarket Notifications.
Under the statutory violations, failure to meet 510(k) requirements for a
device that is required to have a 510(k) and is in commercial distribution
is considered to be:
A. Adulteration.
B. Improper use
C. Misbranded
D. Fraudulent - ANSWER ✔✔C. Misbranded
A marketed device that needs a 510(k) for commercialization but failed
to comply with the requirements is considered to be Misbranded. See
the FD&C Act, 502(o).
A company's competitor is marketing a Class II suture which dissolves
during the third week of use. The company's current product has to be
removed by a physician. However, a change in weaving configuration
COPYRIGHT©NINJANERD 2025/2026. YEAR PUBLISHED 2026. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE. PRIVACY
STATEMENT. ALL RIGHTS RESERVED
3
, gives this product the same dissolving time as the competitor's. When
can the company's new suture be marketed?
A. This requires a new 510(k) since significant change in product
instructions might affect efficacy.
B. After submission in a periodic report
C. After reporting clinical studies in an annual report
D. After submission of labeling change - ANSWER ✔✔A. This
requires a new 510(k) since significant change in product instructions
might affect efficacy.
A new intended use requires a 510(k) clearance.
A physician reports to a manufacturer that a patient was hospitalized
with acute sepsis after treatment with an approved device. This side
effect is not listed in the package insert. This event must be reported by
the manufacturer to FDA no later than:
A. 5 calendar days
B. 15 calendar days